Inkretinmimetika Inkretinmimetika oder GLP-1-Rezeptoragonisten (auch kurz GLP-1-RA oder GLP-1-Agonisten ) sind eine Wirkstoffklasse innerhalb der Antidiabetika, die ursprnglich spezifisch zur Behandlung des Diabetes mellitus Typ 2 entwickelt wurde
An important factor in helping healthcare professionals and their patients decide on the best medication for the individual is determining patient preference on the frequency (daily vs
The GLP-1 antagonist, exendin 939, regulates nociception via TRPV1 modulation Exendin 939, a synthetic peptide, functions as a specific and competitive antagonist of GLP-1 38
Butler J, Shah SJ, Petrie MC, et al
GI AEs may lead to the temporary or permanent discontinuation of GLP-1 RA treatment
They found that, indeed, there was a modest beneficial effect on kidney function even in people without kidney disease, and a larger beneficial effect in slowing rate of kidney function loss in people with kidney disease, explains Shuchi Anand, MD, MS, an associate professor of medicine (nephrology) at Stanford Medicine
